AZENTA ($NASDAQ:AZTA) reported their fourth quarter FY2023 earnings results, with total revenue standing at USD 172.4 million, representing a 25.3% increase from the same period in the previous year. Net income was also up significantly at 116.3%, amounting to USD 3.4 million.
The stock opened at $47.1 and closed at $47.8, up 0.6% from its previous closing price of $47.5. This increase in stock value was driven by the company’s strong performance in the fourth quarter, where sales and profits both exceeded expectations. The strong earnings results were driven by AZENTA‘s continued expansion into new markets and the success of its existing product lines.
In addition, the company is continuing to invest in research and development, which is expected to further bolster growth in the coming quarters. Overall, AZENTA’s fourth quarter results indicate a strong outlook for the company going forward. With its continued expansion and investment in innovative technologies, AZENTA is well-positioned for sustained success in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Azenta. AZENTA_Reports_Fourth_Quarter_FY2023_Earnings_Results”>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Azenta. AZENTA_Reports_Fourth_Quarter_FY2023_Earnings_Results”>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Azenta. AZENTA_Reports_Fourth_Quarter_FY2023_Earnings_Results”>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Azenta are shown below. AZENTA_Reports_Fourth_Quarter_FY2023_Earnings_Results”>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we conducted an analysis of AZENTA’s financials. Our Star Chart shows that AZENTA is strong in asset, medium in dividend, profitability and weak in growth. Investors interested in such a company may be long-term investors looking for steady income and those looking to purchase and hold shares for the long term. Additionally, AZENTA has a high health score of 8/10 considering its cashflows and debt, making it capable to safely ride out any crisis without the risk of bankruptcy. More…
Star Chart Analysis
The company offers a complete suite of products and services that enable researchers to more effectively understand the function and structure of genomes. Azenta‘s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Azenta is a market leader in genomic solutions, with a strong track record of providing the highest quality products and services to its customers. The company’s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Eurobio Scientific, Straumann Holding AG, and Singular Genomics Systems Inc are all major competitors of Azenta in the genomic solutions market.
– Eurobio Scientific ($BER:E8TN)
Eurobio Scientific is a biotechnology company that specializes in the development and commercialization of diagnostic tests and products. The company has a market cap of 198.51M as of 2022 and a Return on Equity of 21.05%. Eurobio Scientific’s products are used in the diagnosis and treatment of diseases, such as cancer, HIV/AIDS, and hepatitis. The company’s products are sold in over 60 countries worldwide.
– Straumann Holding AG ($LTS:0QMV)
As of 2022, Straumann Holding AG has a market cap of 18.02B and a Return on Equity of 21.04%. The company is a leading provider of dental implants and other oral health products and services.
– Singular Genomics Systems Inc ($NASDAQ:OMIC)
Singular Genomics Systems Inc is a company that focuses on providing genomic solutions. Its market cap as of 2022 is 170.64M, and its ROE is -19.33%. The company’s main products are its sequencing services and its software solutions.
Investors may be pleased with AZENTA‘s fourth quarter results for fiscal year 2023. Total revenue rose by 25.3% year-on-year, and net income jumped by an impressive 116.3%. This indicates strong growth and profitability for AZENTA, with the company continuing to outperform its competition and create value for shareholders.
Analysts may look to the company’s future prospects, such as potential investments in new products or markets, to inform their investment decisions. With solid financials and a promising outlook, AZENTA may be an attractive investment opportunity.